

**Amendment to the Claims:**

Listing of the Pending Claims:

Claims 1-35 (Cancelled)

Claim 36 (Currently Amended) A method of cleaving RNA comprising SEQ ID NO:2460 encoded by a mammalian VEGFr1 gene comprising contacting a chemically modified double-stranded ~~ribonucleic~~ nucleic acid (siRNA) molecule with the RNA encoded by VEGFr1 gene under conditions suitable for the cleavage of the RNA encoded by the mammalian VEGFr1 gene, wherein:

- (a) the nucleic acid molecule comprises a separate sense strand and antisense strand, each strand having one or more pyrimidine nucleotides and one or more purine nucleotides;
- (b) each strand of the ~~siRNA~~ nucleic acid molecule comprises about 18 to about 27 nucleotides in length;
- (c) the antisense strand of the nucleic acid molecule comprises 18 to 27 nucleotides that are complementary to the target VEGFr1 RNA;
- (d) the sense strand of the nucleic acid molecule is complementary to the antisense strand, and comprises a portion of the target VEGFr1 RNA sequence of about 18 to 27 nucleotides;
- (e) about 50 to 100 percent of the nucleotides in each of the sense and antisense strands of the nucleic acid molecule are chemically modified with modifications independently selected from the group consisting of 2'-O-methyl, 2'-deoxy-2'-fluoro, 2'-deoxy, phosphorothioate and deoxyabasic modifications; and
- (f) one or more of the purine nucleotides present in one or both strands of the nucleic acid molecule are 2'-O-methyl purine nucleotides and one or more of the pyrimidine nucleotides present in one or both strands of the nucleic acid molecule are 2'-deoxy-2'-fluoro pyrimidine nucleotides.

- ~~(b) — the each strand of the siRNA molecule comprises one or more chemical modifications selected from the group consisting of 2' O-methyl nucleotide, 2' deoxy 2' fluoro nucleotide, and 2' deoxy ribose moiety; and~~
- ~~(c) — one of the strands of the double stranded nucleic acid molecule is complementary to RNA encoded by the mammalian VEGF<sub>r1</sub> gene or a portion thereof and the other strand is complementary to the first strand.~~

- Claim 37      (Cancelled)
- Claim 38      (Currently amended) The method according to claim 36, wherein the ~~siRNA~~ nucleic acid molecule comprises one or more ribonucleotides.
- Claim 39      (Cancelled)
- Claim 40      (Cancelled)
- Claim 41      (Cancelled)
- Claim 42      (Cancelled)
- Claim 43      (Cancelled)
- Claim 44      (Currently Amended) The method according to claim ~~40~~ 36, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 ~~one or more~~ purine of the pyrimidine nucleotides present in the sense ~~region~~ strand are 2'-O-methyl ~~purine~~ pyrimidine nucleotides.
- Claim 45      (Currently Amended) The method according to claim ~~40~~ 36, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 ~~one or more~~ of the purine nucleotides present in the sense ~~region~~ strand are 2'-deoxy purine nucleotides.

- Claim 46 (Currently Amended) The method according to claim ~~40~~ 36, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 ~~one~~ or more of the pyrimidine nucleotides present in the sense ~~region~~ strand are 2'-deoxy-2'-fluoro pyrimidine nucleotides.
- Claim 47 (Currently Amended) The method according to claim ~~40~~ 36, wherein the ~~fragment comprising said~~ sense ~~region~~ strand includes a terminal cap moiety at the 5'-end, the 3'-end, or both of the 5' and 3' ends of the ~~fragment comprising said~~ sense ~~region~~ strand.
- Claim 48 (Currently Amended) The method according to claim 47, wherein ~~said~~ the terminal cap moiety is an inverted deoxy abasic moiety.
- Claim 49 (Currently Amended) The method according to claim ~~40~~ 36, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 ~~one~~ or more of the pyrimidine nucleotides present in ~~said~~ the antisense ~~region~~ strand are 2'-deoxy-2'-fluoro pyrimidine nucleotides
- Claim 50 (Currently Amended) The method according to claim ~~40~~ 36, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 ~~one~~ or more of the purine nucleotides present in ~~said~~ the antisense ~~region~~ strand are 2'-O-methyl purine nucleotides.
- Claim 51 (Currently Amended) The method according to claim ~~40~~ 36, wherein 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 ~~one~~ or more of the purine nucleotides present in ~~said~~ the antisense ~~region~~ comprise strand are 2'-deoxy- purine nucleotides.
- Claim 52 (Currently Amended) The method according to claim ~~40~~ 36, wherein ~~said~~ the antisense ~~region~~ strand comprises a terminal phosphorothioate internucleotide linkage at the 3' end of ~~said~~ the antisense ~~region~~ strand.
- Claim 53 (Cancelled)
- Claim 54 (Cancelled)
- Claim 55 (Cancelled)
- Claim 56 (Previously Presented) The method according to claim 36, wherein the siRNA molecule comprises a first strand having sequence

5'-B CUGAGUUUAAAAGGCACCCTT B-3' (SEQ ID NO: 2185),

and a second strand having sequence

5'-GGGUGCCUUUAAAACUCAGTsT-3' (SEQ ID NO: 2188),

wherein each A, G, C, and U are ribonucleotides, each T is thymidine, s is a phosphorothioate internucleotide linkage, and each B is an inverted deoxyabasic cap moiety.

- Claim 57 (New) The method according to claim 50, wherein 1, 2, or 3 of the purine nucleotides present in the sense strand are 2'-O-methyl purine nucleotides.
- Claim 58 (New) The method according to claim 36, wherein the antisense strand includes a terminal phosphate group.
- Claim 59 (New) The method according to claim 36, wherein the chemically modified double-stranded nucleic acid molecule is in a pharmaceutically acceptable carrier or diluent.